title: ACG Clinical Guideline: Primary Sclerosing Cholangitis.
abstract: Primary sclerosing cholangitis is a chronic cholestatic liver disease that can shorten life and may require liver transplantation. The cause is unknown, although it is commonly associated with colitis. There is no approved or proven therapy, although ursodeoxycholic acid is used by many on an empiric basis. Complications including portal hypertension, fat-soluble vitamin deficiency, metabolic bone diseases, and development of cancers of the bile duct or colon can occur.
authors: 1] College of Health Solutions, Arizona State University, Phoenix, Arizona, USA [2] Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.
authors: Keith D
authors: KD
authors: Lindor
authors: Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle, Washington, USA.
authors: Kris V
authors: KV
authors: Kowdley
authors: Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.
authors: M Edwyn
authors: ME
authors: Harrison
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D002760:Cholangiopancreatography, Endoscopic Retrograde; D015209:Cholangitis, Sclerosing / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D004067:Digestive System Neoplasms / Q000175:diagnosis*; D042882:Gallstones; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis* / Q000453:epidemiology; D016031:Liver Transplantation; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D002756:Cholagogues and Choleretics; D007166:Immunosuppressive Agents; D014580:Ursodeoxycholic Acid